Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -44% Improvement Relative Risk Arabi et al. NCT02735707 REMAP-CAP HCQ RCT ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? RCT 402 patients in multiple countries Higher mortality with HCQ (p=0.015) Arabi et al., Intensive Care Medicine Favors HCQ Favors control
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Arabi et al., Intensive Care Medicine, REMAP-CAP, NCT02735707 (history)
Arabi et al., Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized.., Intensive Care Medicine, REMAP-CAP, NCT02735707
Jul 2021   Source   PDF  
  All Studies   Meta
Very late stage RCT with 50 ICU patients treated with HCQ, 255 lopinavir-ritonavir patients, and 27 combined therapy patients, showing higher mortality with all treatments. Note: the longer term followup results reported in Higgins et al. are included in meta analysis.
risk of death, 44.5% higher, RR 1.44, p = 0.01, treatment 17 of 49 (34.7%), control 106 of 353 (30.0%), adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Arabi et al., 12 Jul 2021, Randomized Controlled Trial, multiple countries, peer-reviewed, 1 author, trial NCT02735707 (history) (REMAP-CAP).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Intensive Care Med (2021) 47:867–886 ORIGINAL Lopinavir‑ritonavir and hydroxychloroquine for critically ill patients with COVID‑19: REMAP‑CAP randomized controlled trial Yaseen M. Arabi1,2,3* , Anthony C. Gordon4,5, Lennie P. G. Derde6,7, Alistair D. Nichol8,9,10, Srinivas Murthy11, Farah Al Beidh4, Djillali Annane12,13,14, Lolowa Al Swaidan2,3,15, Abi Beane16, Richard Beasley17, Lindsay R. Berry18, Zahra Bhimani19, Marc J. M. Bonten7,20, Charlotte A. Bradbury21,22, Frank M. Brunkhorst23, Meredith Buxton24, Adrian Buzgau25, Allen Cheng25,26, Menno De Jong27, Michelle A. Detry18, Eamon J. Duffy28, Lise J. Estcourt29,30, Mark Fitzgerald18, Rob Fowler31,32,33, Timothy D. Girard34,35, Ewan C. Goligher36, Herman Goossens37, Rashan Haniffa38,39,40, Alisa M. Higgins9, Thomas E. Hills17,41, Christopher M. Horvat34,35,42, David T. Huang34,35, Andrew J. King35, Francois Lamontagne43,44, Patrick R. Lawler31,36,45, Roger Lewis18,46, Kelsey Linstrum34,35, Edward Litton47,48,49, Elizabeth Lorenzi18, Salim Malakouti50, Daniel F. McAuley51,52, Anna McGlothlin18, Shay Mcguinness17,25,53, Bryan J. McVerry34,35, Stephanie K. Montgomery34,35, Susan C. Morpeth54, Paul R. Mouncey55, Katrina Orr56, Rachael Parke17,53,57, Jane C. Parker9, Asad E. Patanwala58,59, Kathryn M. Rowan60, Marlene S. Santos19, Christina T. Saunders18, Christopher W. Seymour34,35, Manu Shankar‑Hari61,62, Steven Y. C. Tong63,64, Alexis F. Turgeon65,66, Anne M. Turner17, Frank Leo Van de Veerdonk67, Ryan Zarychanski68, Cameron Green9, Scott Berry18, John C. Marshall19,69, Colin McArthur70, Derek C. Angus34,35 and Steven A. Webb9,48 on behalf of the REMAP-CAP Investigators © 2021 Springer-Verlag GmbH Germany, part of Springer Nature Abstract Purpose: To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19). Methods: Critically ill adults with COVID-19 were randomized to receive lopinavir-ritonavir, hydroxychloroquine, combination therapy of lopinavir-ritonavir and hydroxychloroquine or no antiviral therapy (control). The primary endpoint was an ordinal scale of organ support-free days. Analyses used a Bayesian cumulative logistic model and expressed treatment effects as an adjusted odds ratio (OR) where an OR > 1 is favorable. Results: We randomized 694 patients to receive lopinavir-ritonavir (n = 255), hydroxychloroquine (n = 50), combina‑ tion therapy (n = 27) or control (n = 362). The median organ support-free days among patients in lopinavir-ritonavir, hydroxychloroquine, and combination therapy groups was 4 (– 1 to 15), 0 (– 1 to 9) and—1 (– 1 to 7), respectively, *Correspondence: 1 Intensive Care Department, Ministry of the National Guard-Health Affairs, ICU 1425, P.O. Box 22490, Riyadh 11426, Kingdom of Saudi Arabia Full author information is available at the end of the article The members of “The REMAP-CAP Investigators” are listed in Acknowledgements section. 868 compared to 6 (– 1 to 16) in the control group with in-hospital mortality of 88/249 (35%), 17/49 (35%), 13/26 (50%), respectively, compared to 106/353 (30%) in the control group. The three interventions decreased organ supportfree days compared to control (OR [95% credible interval]: 0.73 [0.55, 0.99], 0.57 [0.35, 0.83] 0.41 [0.24, 0.72]), yielding posterior probabilities that reached the threshold futility (≥ 99.0%), and high probabilities of harm (98.0%, 99.9% and > 99.9%,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop